Profile data is unavailable for this security.
About the company
Fortress Biotech, Inc. is a biopharmaceutical company focused on acquiring and advancing assets. The Company has seven marketed prescription pharmaceutical products and over 25 programs in development at the Company, at its majority-owned and majority-controlled partners and subsidiaries and at partners and subsidiaries it founded and in which it holds significant minority ownership positions. Such product candidates span six market areas, including oncology, rare diseases and gene therapy. Its dermatology products include Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, Exelderm and Luxamend. Its late stage product candidates include Cosibelimab (anti-PD-L1 antibody), DFD-29 (modified release oral minocycline for the treatment of rosacea), CUTX-101 (copper histidinate injection for Menkes disease), IV Tramadol, Olafertinib (also known as CK-101, EGFR inhibitor for EGFR mutation-positive NSCLC), CAEL-101 (monoclonal antibody for AL amyloidosis) and Triplex (cytomegalovirus (CMV) vaccine).
- Revenue in USD (TTM)84.51m
- Net income in USD-68.67m
- Incorporated2006
- Employees186.00
- LocationFortress Biotech Inc1111 KANE CONCOURSE, SUITE 301BAY HARBOR ISLANDS 33154United StatesUSA
- Phone+1 (781) 652-4500
- Fax+1 (781) 652-4545
- Websitehttps://www.fortressbiotech.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Surrozen Inc | 0.00 | -43.04m | 31.86m | 42.00 | -- | 0.5417 | -- | -- | -21.35 | -21.35 | 0.00 | 18.39 | 0.00 | -- | -- | 0.00 | -63.52 | -- | -72.56 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -100.00 | -- | -19.55 | -- | -- | -- |
| Singular Genomics Systems Inc | 2.91m | -94.82m | 31.87m | 255.00 | -- | 0.1778 | -- | 10.95 | -1.30 | -1.30 | 0.04 | 2.42 | 0.0098 | 0.2182 | 3.94 | 11,415.69 | -31.96 | -- | -33.80 | -- | -19.17 | -- | -3,257.30 | -- | 9.77 | -- | 0.0474 | -- | 280.52 | -- | -4.34 | -- | -- | -- |
| Viracta Therapeutics Inc | 0.00 | -51.06m | 32.20m | 40.00 | -- | 2.49 | -- | -- | -1.32 | -1.32 | 0.00 | 0.4686 | 0.00 | -- | -- | 0.00 | -66.88 | -86.35 | -97.91 | -106.38 | -- | -- | -- | -11,853.94 | -- | -141.21 | 0.5798 | -- | -- | -- | -3.78 | -- | -- | -- |
| Mink Therapeutics Inc | 0.00 | -22.46m | 32.28m | 31.00 | -- | -- | -- | -- | -0.6538 | -0.6538 | 0.00 | -0.5219 | 0.00 | -- | -- | 0.00 | -172.59 | -- | -2,317.47 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 19.77 | -- | -- | -- |
| Spruce Biosciences Inc | 10.09m | -47.92m | 32.90m | 29.00 | -- | 0.4288 | -- | 3.26 | -1.26 | -1.26 | 0.2622 | 1.86 | 0.1064 | -- | -- | 347,896.60 | -50.55 | -41.24 | -62.77 | -46.49 | -- | -- | -474.96 | -1,774.39 | -- | -107.65 | 0.0418 | -- | -- | -- | -3.77 | -- | -- | -- |
| Palatin Technologies, Inc. | 7.10m | -30.91m | 33.56m | 34.00 | -- | -- | -- | 4.73 | -2.48 | -2.48 | 0.5582 | -0.7956 | 0.3118 | 0.8717 | 3.42 | 208,755.90 | -135.79 | -26.11 | -269.84 | -30.68 | 95.34 | -- | -435.53 | -126.20 | 1.09 | -- | -- | -- | 230.53 | -40.87 | 23.91 | -- | 80.82 | -- |
| IGC Pharma Inc | 1.22m | -14.15m | 33.65m | 61.00 | -- | 3.56 | -- | 27.67 | -0.2479 | -0.2479 | 0.0217 | 0.142 | 0.0776 | 0.2084 | 7.09 | 19,934.43 | -90.30 | -33.35 | -100.90 | -35.84 | 51.40 | 8.74 | -1,163.24 | -410.26 | 0.8564 | -- | 0.0153 | -- | 129.47 | -16.11 | 23.38 | -- | 25.28 | -- |
| LianBio - ADR | 0.00 | -87.98m | 34.05m | 163.00 | -- | 0.1669 | -- | -- | -0.8195 | -0.8195 | 0.00 | 1.89 | 0.00 | -- | -- | 0.00 | -28.62 | -- | -35.22 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 43.82 | -- | -- | -- |
| Fortress Biotech Inc | 84.51m | -68.67m | 34.24m | 186.00 | -- | 1.19 | -- | 0.4051 | -8.88 | -8.88 | 10.29 | 1.49 | 0.366 | 2.19 | 3.89 | 454,371.00 | -66.76 | -52.50 | -117.74 | -99.46 | 68.45 | 63.17 | -182.40 | -236.94 | 1.26 | -11.31 | 0.9758 | -- | 11.58 | 25.75 | 27.42 | -- | -9.37 | -- |
| CASI Pharmaceuticals Inc | 33.88m | -26.96m | 34.98m | 176.00 | -- | 1.44 | -- | 1.03 | -2.02 | -2.02 | 2.54 | 1.81 | 0.3951 | 1.26 | 3.01 | 192,494.30 | -30.57 | -34.75 | -45.42 | -46.91 | 59.19 | 55.98 | -77.37 | -153.72 | 2.60 | -- | 0.4388 | -- | -21.41 | -- | 34.27 | -- | 14.65 | -- |
| Nuo Therapeutics Inc | 608.53k | -3.17m | 35.35m | -- | -- | 34.02 | -- | 58.09 | -0.0754 | -0.0754 | 0.0145 | 0.0235 | 0.2471 | 0.5609 | 3.55 | -- | -128.78 | -116.16 | -173.76 | -354.84 | 79.28 | 70.02 | -521.17 | -854.53 | 2.01 | -1,002.61 | 0.00 | -- | 442.12 | -14.99 | 0.0095 | -- | -- | -- |
| Marker Therapeutics Inc | 3.31m | -14.05m | 35.83m | 8.00 | -- | 2.55 | -- | 10.82 | -1.59 | -0.933 | 0.3753 | 1.58 | 0.1285 | -- | 1.93 | 413,892.50 | -54.49 | -53.74 | -69.03 | -62.25 | -- | -- | -424.20 | -1,438.71 | -- | -- | 0.00 | -- | -5.76 | 74.27 | 28.97 | -- | -- | -- |
| Apollomics Inc | 0.00 | -388.09m | 36.02m | -- | -- | 0.6466 | -- | -- | -4.34 | -4.34 | 0.00 | 0.6225 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -1,391.69 | 0.012 | -- | -- | -- | -154.03 | -- | -- | -- |
| Promis Neurosciences Inc | 0.00 | -13.21m | 36.05m | 6.00 | -- | 9.57 | -- | -- | -1.22 | -1.22 | 0.00 | 0.1987 | 0.00 | -- | -- | 0.00 | -128.63 | -144.28 | -552.70 | -262.23 | -- | -- | -- | -2,271,047.00 | -- | -- | 0.00 | -- | -- | -- | 26.85 | -- | -- | -- |
Data as of May 08 2024. Currency figures normalised to Fortress Biotech Inc's reporting currency: US Dollar USD
21.28%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Heights Capital Management, Inc.as of 31 Dec 2023 | 764.55k | 4.16% |
| Rosalind Advisors, Inc.as of 31 Mar 2024 | 607.80k | 3.31% |
| Armistice Capital LLCas of 31 Dec 2023 | 596.00k | 3.24% |
| Altium Capital Management LPas of 31 Dec 2023 | 405.12k | 2.21% |
| Nantahala Capital Management LLCas of 31 Dec 2023 | 372.56k | 2.03% |
| The Vanguard Group, Inc.as of 31 Dec 2023 | 351.86k | 1.92% |
| Hudson Bay Capital Management LPas of 31 Dec 2023 | 327.24k | 1.78% |
| Shikiar Asset Management, Inc.as of 31 Mar 2024 | 223.14k | 1.21% |
| PVG Asset Management Corp.as of 31 Dec 2023 | 131.49k | 0.72% |
| Acadian Asset Management LLCas of 31 Dec 2023 | 130.19k | 0.71% |
More ▼
Data from 31 Dec 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
